Reata Pharmaceuticals — Technical Presentation (November 2017)
30 slides from Reata Pharmaceuticals's technical presentation, Nov 6, 2017
Slide 1: Program update of Bardoxolone Methyl in CKD
Program update of Bardoxolone Methyl in CKD Exhibit 99.2
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains certain “forward-looking” statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical or present facts, are forward-looking statement
Slide 3: Outline for Bardoxolone CKD Program Update
Outline for Bardoxolone CKD Program Update Review of Phase 2 CARDINAL data Review of Phase 2 TSUBAKI data Other pharmacologic effects of bardoxolone in CKD patients Overview of PHOENIX program Questions
Slide 4: CARDINAL Phase 2 data review
Cardinal phase 2 data review
Slide 5: CARDINAL Phase 2 Open-Label Study Design
CARDINAL Phase 2 Open-Label Study Design Enrolled 30 patients with genetic or histologic confirmation of Alport syndrome Dose-titration scheme used to reach goal dose of 20 or 30 mg given orally, once daily Primary efficacy endpoint: change from baseline in eGFR at Week 12 Key eligibility criteria:
Slide 6: Phase 2 Primary Efficacy Analysis
Phase 2 Primary Efficacy Analysis All patients completed treatment through Week 12 eGFR data show time-dependent increases through Week 12 Changes consistent with Bard treatment in prior diabetic CKD studies Change from Baseline in eGFR Week 1 Week 4 Week 8 Week 12 N 30 30 30 30 Mean ± SE 3.0 ± 0.7
Slide 7: Distribution of eGFR Changes
Distribution of eGFR Changes All patients demonstrated eGFR increases from baseline 87% of patients demonstrated increases of at least 4 ml/min/1.73 m2 63% of patients demonstrated increases of at least 10 ml/min/1.73 m2 22/30 (73%) of patients had an improvement in CKD stage and none worsened Basel
Slide 8: eGFR Changes by Subgroups
eGFR Changes by Subgroups Clinically meaningful increases in eGFR across multiple subgroups Activity in earlier and later stages of disease Baseline Characteristic Subgroup N Baseline Week 12 Mean ΔeGFR Change ± SD % Change eGFR ≥ 60 12 81.3 ± 7.5 18.4 ± 7.7 23% < 60 18 36.1 ± 9.3 10.0 ± 6.6 30% UAC
Slide 9: Summary of Safety
Summary of Safety No discontinuations No serious adverse events AEs to date have generally been mild to moderate in intensity No reports of fluid overload No consistent AEs to date, except muscle spasms Also observed in prior diabetic CKD trials Present as contraction, usually in the lower extremity
Slide 10: Blood Pressure and BNP
Blood Pressure and BNP Patients with poorly controlled hypertension or BNP > 200 pg/mL were ineligible Blood pressure and volume status under control upon study entry and maintained post-initiation of treatment Average BNP upon entry was 1/10th allowable limit and 1/5th ULN Median BNP levels maintai
Slide 11: Urine Albumin to Creatinine Ratio
Urine Albumin to Creatinine Ratio Increases in UACR with Bard consistent with increases in filtration (↑ GFR) Normalization of UACR with eGFR show UACR/eGFR ratios are unchanged from baseline UACR (Log UACR) / eGFR Ratio
Slide 12: Conclusions
Conclusions Phase 2 CARDINAL study demonstrates bardoxolone methyl significantly increases eGFR in patients with Alport syndrome after 12 weeks of treatment eGFR increases in CARDINAL were observed over full range of baseline eGFR values (range: 28 to 94 mL/min/1.73 m2) and across multiple subgroups
Slide 13: TSUBAKI Phase 2 data review
tsubaki phase 2 data review
Slide 14: Design and Objectives
Design and Objectives Randomized, double-blind, placebo controlled, multi-center Phase 2 trial Evaluated efficacy (GFR) and safety of Bard Patients with Stage 3 (n= 85) to Stage 4 (n=39) CKD and type 2 diabetes Excluded patients with identified risk factors for fluid overload Used standard inulin cl
Slide 15: Primary Endpoint: Significant Increase in GFR as Assessed by Inulin Clearance
Primary Endpoint: Significant Increase in GFR as Assessed by Inulin Clearance Bard significantly increased GFR from baseline relative to placebo at Week 16 Placebo N=23 BARD N=17 GFR (mL/min) Baseline, mean±SD 48.1 ± 9.9 49.0 ± 9.6 Week 16, mean±SD 47.7 ± 11.6 54.5 ± 12.2 LS mean difference -0.69 5.
Slide 16: No Changes in Urinary Creatinine Excretion, Urine Output, or Sodium Excretion
No Changes in Urinary Creatinine Excretion, Urine Output, or Sodium Excretion No change in urinary creatinine excretion, suggesting that: Bard is unlikely to affect creatinine production Bard is unlikely to reduce muscle mass No changes in urine volume or sodium excretion Consistent with lack of BP
Slide 17: No Increases in Blood Pressure or Troponin T
No Increases in Blood Pressure or Troponin T Increases in GFR not associated with changes in BP Bard not associated with any evidence of cardiotoxicity, as assessed by Troponin T
Slide 18: Adverse Events
Adverse Events Adverse Events that Occurred in ≥ 15% of Patients Placebo N = 41 BARD N = 41 Subjects with any TEAE 28 (68.3) 38 (92.7) Viral upper respiratory tract infection 6 (14.6) 8 (19.5) Alanine aminotransferase (ALT) increased 1 (2.4) 16 (39.0) Aspartate aminotransferase (AST) increased 1 (2.
Slide 19: Conclusions and Summary
Conclusions and Summary BARD significantly improved renal function (GFR) as assessed by inulin clearance By prospectively enrolling patients who were not at-risk for fluid retention, BARD appeared well tolerated without any major safety concerns No fluid overload-related hospitalizations No new safe
Slide 20: Other Pharmacologic Effects of Bardoxolone in CKD
Other Pharmacologic Effects of bardoxolone in ckd
Slide 21: Bard Mechanism of Action Extensively Characterized
Bard Mechanism of Action Extensively Characterized Reata observed unprecedented increases in kidney function in early clinical trials in cancer patients Reata and collaborators extensively characterized Bard effects on kidney (150+ published papers) Both acute and chronic kidney disease, regardless
Slide 22: Despite Study Termination, Bard Increased eGFR and Reduced Kidney Failure Outcomes in BEACON
Despite Study Termination, Bard Increased eGFR and Reduced Kidney Failure Outcomes in BEACON Bard significantly increased eGFR (p<0.0001) and increases were durable through at least one year Reduced ESRD and renal SAE events Significantly reduced likelihood of kidney failure outcomes, including comp
Slide 23: Increases in Kidney Function are Partially Retained After Withdrawal of Bard
Increases in Kidney Function are Partially Retained After Withdrawal of Bard Kidney function increased after one year of treatment followed by washout eGFR assessed after one year of treatment followed by 4 week withdrawal Four week withdrawal corresponds to three weeks after loss of pharmacologic a
Slide 24: Profile of Bardoxolone Methyl is Inconsistent with Pressure-Mediated Hyperfiltration
Profile of Bardoxolone Methyl is Inconsistent with Pressure-Mediated Hyperfiltration Pressure-mediated hyperfiltration can increase eGFR short-term but damage glomeruli and cause more rapid eGFR decline long-term1-5 Demonstrated preclinically using 5/6 nephrectomy model of hyperfiltration5 Demonstra
Slide 25: Increases in Urinary Protein are Consistent with Increases in GFR and not Injury
Increases in Urinary Protein are Consistent with Increases in GFR and not Injury 1Lazzara, AJP Renal Physiol (2007); 2Rossing, ASN Poster (2012); 3Manuscript in preparation In CKD, damage to the glomerular filtration barrier results in loss of selectivity, increased filtration of protein and subsequ
Slide 26: PHOENIX Phase 2 program overview
phoenix phase 2 program overview
Slide 27: Bard Targets Common Phenotype Shared by Many Types of Chronic Kidney Disease
Bard Targets Common Phenotype Shared by Many Types of Chronic Kidney Disease Bard targets inflammatory processes that degrade renal function in many forms of CKD CARDINAL results to date and existing body of data encourage study of bard in additional, rare renal diseases Initial target indications i
Slide 28: PHOENIX Program Underway
PHOENIX Program Underway Similar to CARDINAL Phase 2 design: 12 weeks of open-label treatment, titration to goal dose of 20 or 30 mg of Bard orally, once daily Key eligibility criteria similar to CARDINAL design Stable doses of background meds (ACEi, ARB, insulin, prednisone, etc.) Will enroll 20-30
Slide 29: Upcoming Key CKD Program Milestones
Upcoming Key CKD Program Milestones Phase 3 portion of the CARDINAL trial began enrollment during August 2017 and one year data are expected 2H 2019 Site activations in PHOENIX Phase 2 trial to study Bard in four additional rare kidney indications are underway Enrolling patients with Autosomal Domin
Slide 30: Q&A
Q&A
Reata Pharmaceuticals — Technical Presentation (November 2017) on 6ix